FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2749492030> ?p ?o ?g. }

• W2749492030 endingPage "2009" @default.
• W2749492030 startingPage "2001" @default.
• W2749492030 abstract "To compare the 3-year follow-up results of intravitreal injections of aflibercept between fixed dosing (FD) regimen and a pro re nata (PRN) regimen after three initial monthly doses for the treatment of polypoidal choroidal vasculopathy and to analyze factors influencing improvement in visual acuity.We retrospectively studied all treatment-naive patients with polypoidal choroidal vasculopathy who were scheduled to receive intravitreal aflibercept injections FD or PRN after induction treatment between March 2013 and May 2014. Best-corrected visual acuity was evaluated before treatment and at 4, 12, 24, and 36 months after initial treatment. Factors that influence improvement in visual acuity were also investigated.Thirty-three eyes were assessed at the 3-year follow-up examination. Twenty-three eyes were treated with intravitreal aflibercept injections every 2 months for at least 1 year after three initial monthly doses (FD group), and 10 eyes were treated PRN after loading doses (PRN group). In the FD group, during the follow-up period from 1 to 3 years, quarterly dosing with capped PRN or a treat and extend regimen were selected. The mean number of administered intravitreal aflibercept was 15.3 ± 4.6 in the FD group and 9.0 ± 8.9 in the PRN group, with a significant difference between the two groups (P = 0.004). Significant improvement of the mean logarithm of the minimum angle of resolution values for best-corrected visual acuity was shown at 36 months, as compared to baseline values (P = 0.019). No significant difference in the improvement of best-corrected visual acuity between the two groups was observed at baseline or at 4, 12, 24, and 36 months after treatment (all P > 0.05), although there was a trend toward better results in the FD group. Multiple regression analysis showed that the FD group had better visual acuity at 36 months and greater improvement in visual acuity than the PRN group (P = 0.031 for both comparisons).Intravitreal aflibercept was effective in improving the vision of patients with polypoidal choroidal vasculopathy, as evaluated at the 3-year follow-up. Fixed treatment might be an important factor influencing improvement in visual acuity." @default.
• W2749492030 created "2017-08-31" @default.
• W2749492030 creator A5000309836 @default.
• W2749492030 creator A5001242776 @default.
• W2749492030 creator A5044411658 @default.
• W2749492030 creator A5048213684 @default.
• W2749492030 date "2018-10-01" @default.
• W2749492030 modified "2023-09-27" @default.
• W2749492030 title "INTRAVITREAL INJECTION OF AFLIBERCEPT IN PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY" @default.
• W2749492030 cites W1768895213 @default.
• W2749492030 cites W1870696162 @default.
• W2749492030 cites W193593035 @default.
• W2749492030 cites W1968189763 @default.
• W2749492030 cites W1970803198 @default.
• W2749492030 cites W1974272630 @default.
• W2749492030 cites W2004117352 @default.
• W2749492030 cites W2007590058 @default.
• W2749492030 cites W2007786900 @default.
• W2749492030 cites W2045317893 @default.
• W2749492030 cites W2055522471 @default.
• W2749492030 cites W2077129920 @default.
• W2749492030 cites W2078573046 @default.
• W2749492030 cites W2083043469 @default.
• W2749492030 cites W2092462226 @default.
• W2749492030 cites W2097487722 @default.
• W2749492030 cites W2106466837 @default.
• W2749492030 cites W2110960237 @default.
• W2749492030 cites W2131797455 @default.
• W2749492030 cites W2139795069 @default.
• W2749492030 cites W2150416945 @default.
• W2749492030 cites W2198221747 @default.
• W2749492030 cites W2257990108 @default.
• W2749492030 cites W2309500182 @default.
• W2749492030 cites W2316418129 @default.
• W2749492030 cites W2318417808 @default.
• W2749492030 cites W2396715106 @default.
• W2749492030 cites W2410238363 @default.
• W2749492030 cites W2486265314 @default.
• W2749492030 cites W2511233293 @default.
• W2749492030 cites W2519471690 @default.
• W2749492030 cites W2523867766 @default.
• W2749492030 cites W2529266562 @default.
• W2749492030 cites W2559978819 @default.
• W2749492030 cites W4232841428 @default.
• W2749492030 cites W4241340854 @default.
• W2749492030 cites W4249438516 @default.
• W2749492030 doi "https://doi.org/10.1097/iae.0000000000001818" @default.
• W2749492030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28816730" @default.
• W2749492030 hasPublicationYear "2018" @default.
• W2749492030 type Work @default.
• W2749492030 sameAs 2749492030 @default.
• W2749492030 citedByCount "17" @default.
• W2749492030 countsByYear W27494920302017 @default.
• W2749492030 countsByYear W27494920302018 @default.
• W2749492030 countsByYear W27494920302019 @default.
• W2749492030 countsByYear W27494920302020 @default.
• W2749492030 countsByYear W27494920302021 @default.
• W2749492030 countsByYear W27494920302022 @default.
• W2749492030 crossrefType "journal-article" @default.
• W2749492030 hasAuthorship W2749492030A5000309836 @default.
• W2749492030 hasAuthorship W2749492030A5001242776 @default.
• W2749492030 hasAuthorship W2749492030A5044411658 @default.
• W2749492030 hasAuthorship W2749492030A5048213684 @default.
• W2749492030 hasConcept C118487528 @default.
• W2749492030 hasConcept C126322002 @default.
• W2749492030 hasConcept C141071460 @default.
• W2749492030 hasConcept C2776694085 @default.
• W2749492030 hasConcept C2777288759 @default.
• W2749492030 hasConcept C2777802072 @default.
• W2749492030 hasConcept C2778257484 @default.
• W2749492030 hasConcept C2778749236 @default.
• W2749492030 hasConcept C2780699112 @default.
• W2749492030 hasConcept C2781100027 @default.
• W2749492030 hasConcept C2781413609 @default.
• W2749492030 hasConcept C71924100 @default.
• W2749492030 hasConceptScore W2749492030C118487528 @default.
• W2749492030 hasConceptScore W2749492030C126322002 @default.
• W2749492030 hasConceptScore W2749492030C141071460 @default.
• W2749492030 hasConceptScore W2749492030C2776694085 @default.
• W2749492030 hasConceptScore W2749492030C2777288759 @default.
• W2749492030 hasConceptScore W2749492030C2777802072 @default.
• W2749492030 hasConceptScore W2749492030C2778257484 @default.
• W2749492030 hasConceptScore W2749492030C2778749236 @default.
• W2749492030 hasConceptScore W2749492030C2780699112 @default.
• W2749492030 hasConceptScore W2749492030C2781100027 @default.
• W2749492030 hasConceptScore W2749492030C2781413609 @default.
• W2749492030 hasConceptScore W2749492030C71924100 @default.
• W2749492030 hasIssue "10" @default.
• W2749492030 hasLocation W27494920301 @default.
• W2749492030 hasLocation W27494920302 @default.
• W2749492030 hasOpenAccess W2749492030 @default.
• W2749492030 hasPrimaryLocation W27494920301 @default.
• W2749492030 hasRelatedWork W2009326523 @default.
• W2749492030 hasRelatedWork W2616226964 @default.
• W2749492030 hasRelatedWork W2788600131 @default.
• W2749492030 hasRelatedWork W2913637396 @default.
• W2749492030 hasRelatedWork W2967930139 @default.
• W2749492030 hasRelatedWork W2981977889 @default.

• next